|
|
Adaptimmune Therapeutics PLC
|
| General Information |
| Business: |
We are a clinical-stage biopharmaceutical company focused on novel cancer immunotherapy products based on our T-cell receptor platform. We have developed a comprehensive proprietary platform that enables us to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates for administration to patients. We engineer TCRs to increase their affinity to cancer-specific peptides, including our lead target peptides, NY-ESO-1 and MAGE A-10, in order to target and then destroy cancer cells in patients. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
103 |
Founded: |
2015 |
|
| Contact Information |
| Address: |
91 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY, United Kingdom |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 4.4 mil (last 12 months) |
|
| Net Income: |
$ -11.6 mil (last 12 months) |
|
| IPO Profile |
| Symbol: |
ADAP |
| Shares (millions): |
11.3 |
| Price Range: |
$17.00 - $17.00 |
| Est.$ Volume |
$ 191.3 mil |
| Manager / Joint Managers |
BofA Merrill Lynch/ Cowen and Company/ Leerink Partners |
| Co Managers |
Guggenheim Securities |
| Expected to Trade |
5/6/2015 |
| Status |
Priced |
| SCOOP RATING |
Available only to Subscribers |
| RATING CHANGE |
Available only to Subscribers |
|
|
|
|
